Citadel Advisors LLC
- SEC CIK
- 0001423053
- Latest filing
- Sep 1, 2026
GALT holding history
Galectin Therapeutics Inc in every 13F filed by Citadel Advisors LLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
GALT overviewAll 13F holders of GALTFull Q2 2026 holdings
- Shares (Q2 2026)
- 198,701
- Value
- $922.0K
- % of portfolio
- <0.1%
- Quarters held
- 13
- Since Q3 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 198,701 | $922.0K | <0.1% | −91,659−31.6% | Reduced | Holders |
| Q1 2026 | 290,360 | $810.1K | <0.1% | +290,360 | New | Holders |
| Q4 2025 | 0 | $0 | 0.0% | −71,306−100.0% | Sold out | Holders |
| Q3 2025 | 71,306 | $302.0K | <0.1% | −31,991−31.0% | Reduced | Holders |
| Q2 2025 | 103,297 | $218.0K | <0.1% | +103,297 | New | Holders |
| Q3 2024 | 0 | $0 | 0.0% | −823−100.0% | Sold out | Holders |
| Q2 2024 | 823 | $1.86K | <0.1% | −23,698−96.6% | Reduced | Holders |
| Q1 2024 | 24,521 | $58.6K | <0.1% | +17,511+249.8% | Added | Holders |
| Q4 2023 | 7,010 | $11.6K | <0.1% | +7,010 | New | Holders |
| Q3 2023 | 0 | $0 | 0.0% | −428−100.0% | Sold out | Holders |
| Q2 2023 | 428 | $616 | <0.1% | −850−66.5% | Reduced | Holders |
| Q1 2023 | 1,278 | $2.68K | <0.1% | −82,356−98.5% | Reduced | Holders |
| Q4 2022 | 83,634 | $94.5K | <0.1% | +65,494+361.0% | Added | Holders |
| Q3 2022 | 18,140 | $29.0K | <0.1% | +18,140 | New | Holders |
| Q1 2022 | 0 | $0 | 0.0% | −43,382−100.0% | Sold out | Holders |
| Q4 2021 | 43,382 | $90.0K | <0.1% | +18,950+77.6% | Added | Holders |
| Q3 2021 | 24,432 | $95.0K | <0.1% | +24,432 | New | Holders |